RSLV 145
Alternative Names: RSLV-145Latest Information Update: 26 Jun 2024
At a glance
- Originator Resolve Therapeutics
- Class Anti-inflammatories; Antihaemorrhagics; Deoxyribonucleases; Immunoglobulin Fc fragments; Recombinant fusion proteins; Ribonucleases; Urologics; Vascular disorder therapies
- Mechanism of Action Deoxyribonuclease replacements; Ribonuclease replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Lupus nephritis; Subarachnoid haemorrhage; Systemic lupus erythematosus; Vasculitis
Most Recent Events
- 26 Jun 2024 Preclinical trials in Lupus nephritis in USA (Parenteral) prior to June 2024 (Resolve Therapeutics pipeline, June 2024)
- 26 Jun 2024 Preclinical trials in Systemic lupus erythematosus in USA (Parenteral) prior to June 2024 (Resolve Therapeutics pipeline, June 2024)
- 20 Dec 2023 Preclinical trials in Autoimmune disorders in USA (unspecified route) before December 2023 (Resolve Therapeutics pipeline, December 2023)